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Objective: Reports evaluating the efficacy of heparin-bonded circuits to blunt
inflammation, platelet dysfunction, and thrombin generation in response to cardio-
pulmonary bypass have varied. We hypothesized that this variability may in part be
related to the use of cardiotomy suction, which has been demonstrated to reintroduce
procoagulant and proinflammatory factors into the systemic circulation during
cardiopulmonary bypass. A prospective, randomized study was undertaken to eval-
uate the specific effects of cardiotomy suction.
Methods: Thirty-six patients undergoing first-time, nonemergency coronary artery
bypass grafting with cardiopulmonary bypass were randomly assigned to one of
three treatment groups: group I, non–heparin-bonded circuits with the use of
cardiotomy suction (n  12); group II, Duraflo II (BCR-3500; Jostra Bentley Corp,
Irvine, Calif) heparin-bonded circuits with cardiotomy suction (n  12); and group
III, Duraflo II heparin-bonded circuits without cardiotomy suction (n 12). Throm-
bin generation, neutrophil activation (polymorphonuclear elastase), platelet activa-
tion (-thromboglobulin), and neuronal injury (neuron-specific enolase) were ana-
lyzed by enzyme-linked immunosorbent assays after cardiopulmonary bypass and
compared with prebypass levels. Results are presented as mean  SEM.
Results: Prebypass levels of all markers were similar among treatment groups.
However, postbypass levels were significantly and consistently highest in group I
relative to groups II and III. Thrombin generation levels were 5.0  0.9 nmol/L in
group I, 3.0  0.6 nmol/L in group II, and 1.5  0.1 nmol/L in group III (P  .05
vs group II and P .001 vs group I). Polymorphonuclear elastase levels were 307
64 g/L in group I, 128  24 g/L in group II (P  .05 vs group I), and 75  14
g/L in group III (P  .001 vs group I). -Thromboglobulin levels were 2692 
401 IU/mL in group I, 912 99 IU/mL in group II (P .001 vs group I), and 646
133 IU/mL in group III (P  .001 vs group I). Neuron-specific enolase levels were
9.8  0.9 ng/mL in group I, 10.5  1.6 ng/mL in group II, and 4.2  0.5 ng/mL
in group III (P  .001 vs groups I and II).
Conclusions: Use of cardiotomy suction resulted in significant increases in throm-
bin, neutrophil, and platelet activation, as well as the release of neuron-specific
enolase, after cardiopulmonary bypass. Limiting increases in these markers would
be best accomplished by eliminating cardiotomy suction and routinely using hep-
arin-bonded circuits whenever possible.
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Heparin-bonded circuits (HBCs) have beendemonstrated to blunt complement, neu-trophil, and platelet activation as well asfibrinolysis and chemokine and cytokineexpressions in patients undergoing coro-nary artery bypass grafting (CABG).1-7
The clinical significance of these blunted responses is still
being debated.8 Many clinicians believe that these markers
are of scientific interest but little clinical relevance. Clini-
cally the use of HBCs has been associated with reductions
in postoperative bleeding, transfusion requirements, need
for inotropic support, pulmonary dysfunction, and throm-
boembolic complications.4,9-14 These improvements trans-
late to decreased intensive care unit (ICU) and hospital stays
and therefore to decreased cost.9 Our previous work docu-
mented that these improvements were due both to the use of
HBCs and to a lower anticoagulation protocol.10 All studies
to date have demonstrated that HBCs are safe. Although
some clinical trials demonstrated improvement in clinical
outcomes in all patients undergoing CABG,4,9-14 however,
other trials have demonstrated more modest clinical im-
provements only in higher-risk patient populations.15-17
We hypothesized that the difference in the reported ef-
ficacy of HBCs and observed clinical outcomes may be due
to variations in cardiopulmonary bypass (CPB) techniques
between institutions. Specifically, we hypothesized that the
use of cardiotomy suction may significantly and adversely
impact the pathophysiologic perturbations noted in re-
sponses to CPB. The potential clinical benefits associated
with HBCs may not be evident when cardiotomy suction is
used routinely, because cardiotomy suction may directly
contribute to elevations in markers of inflammation, platelet
activation, and thrombin generation. Recent animal and
human studies documented that cardiotomy suction may
result in platelet activation, thrombin generation, and re-
lease of inflammatory cytokines.18-23 In addition, mediasti-
nal debris (primarily fat emboli) may be introduced into the
CPB circuit and the systemic circulation.18 This fat easily
deforms and is not eliminated by arterial filters. Emboliza-
tion of atherosclerotic aortic debris, fat, and defoaming
agents, as well as inflammation leading to central nervous
system edema, have been implicated as causes of neurologic
and neuropsychologic dysfunction after valve and CABG
procedures. These injuries have been associated with eleva-
tions in markers of neuronal injury, including serum glial
protein (S100) and neuron-specific enolase (NSE).24-33
This prospective, randomized trial was designed to assess
and disassociate the independent effects of the use of HBCs
and cardiotomy suction on plasma markers of inflammation,
thrombin generation, and platelet activation, as well as
serum markers of neurologic injury, in patients undergoing
CABG with CPB.
Patients and Methods
Study Design
The protocol was reviewed and approved by the human subjects
institutional review boards at the University of Washington and
Northwest Hospital. Informed consent was obtained with adher-
ence to guidelines set forth in the Helsinki Declaration. Patients
were included if the following criteria were met: (1) they were
undergoing primary, nonemergency, on-pump CABG revascular-
ization; (2) they were at least 18 and less than 90 years of age; and
(3) they did not have a preoperative intra-aortic balloon pump or
assist device. Patients were excluded from the study for the fol-
lowing reasons: (1) left ventricular ejection fraction less than 25%,
(2) allergy to heparin or heparin-induced thrombocytopenia, (3)
steroid treatment, (4) inability to perform the neuropsychologic
test battery, (5) other vascular surgery planned with the CABG
(such as aortic arch, carotid endarterectomy, or ventricular aneu-
rysmectomy), (6) dementia, (7) alcohol or drug abuse, (8) hered-
itary complement deficiency, (9) any serious medical condition
that would bias the study or endanger the patient with respect to
taking part in the study, and (10) inability to fully understand any
of the aspects of the protocol or provide informed, written consent.
Prognostic factors, such as pulmonary hypertension, congestive
heart failure, chronic obstructive pulmonary disease, diabetes,
previous myocardial infarction, and preoperative anticoagulant or
antiplatelet agents, were noted. Demographic and cardiac variables
(age, sex, height, weight, left ventricular ejection fraction, body
surface area, Canadian Classification System class, and New York
Heart Association functional class) were also noted. Operative and
postoperative variables were tabulated for later analysis across
groups.
The study design involved random assignment of each subject
to one of three treatment arms: group I, non-HBCs with cardiot-
omy suction; group II, HBCs with cardiotomy suction; and group
III, HBCs with cardiotomy suction eliminated. The numbers of
subjects in the three treatment groups were based on a power
calculation from previous laboratory data that demonstrated a 50%
reduction in markers for coagulation (prothrombin fragments 1.2
[PF1.2], thrombin-antithrombin) and inflammation (interleukin-8,
polymorphonuclear elastase [PMNE]) with use of HBCs. A com-
puter-generated randomization scheme was produced by the in-
vestigational drug pharmacist before the study. Patients undergo-
ing primary, nonemergency CABG were enrolled into the study
after giving written consent. Patients were assigned to one of three
study groups by the perfusionist on the basis of the randomization
scheme. Clinical pathways leading to transfusion, weaning from
ventilator support, discharge from the ICU, and hospital were
standardized. The postoperative team was blinded to treatment
group assignment.
Cardiotomy Suction Versus No Cardiotomy Suction:
Bypass Equipment
Group I. Suctioned cardiotomy blood was forwarded from the
field to hard-shell, non–heparin-coated cardiotomy reservoirs
(COBE 09F4798; COBE Cardiovascular, Inc, Arvada, Colo), as
was vented blood from the aorta. The CPB circuit was composed
of a non–heparin-coated hard-shell venous reservoir with peristal-
tic pump and membrane oxygenators (AFFINITY CVR model
2000; Medtronic Perfusion Systems, Minneapolis, Minn).
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Group II. Suctioned cardiotomy blood was forwarded from
the field to hard-shell, heparin-coated, cardiotomy reservoirs (Du-
raflo II BCR-3500; Jostra Bentley Corp, Irvine, Calif), as was
vented blood from the aorta. The CPB circuit was composed of
heparin-coated, collapsible, soft-shell venous reservoirs (BMR-
1900; Jostra Bentley) with centrifugal pumps (Sarns Centrifugal
System; Terumo Cardiovascular Systems, Corp, Ann Arbor, Mich)
and membrane oxygenators (Spiralgold, Jostra).
Group III. Suctioned blood from the field was directed to the
cell saver (COBE BRAT II). Vented aortic blood was directed to
a heparin-coated, collapsible, soft-shell venous reservoir (BMR-
1900), as was vented blood from the aorta. The CPB circuit was
composed of a centrifugal pump (Sarns Centrifugal System) and a
heparin-coated membrane oxygenator (Spiralgold).
All groups. Activated clotting times (ACTs) were maintained
at longer than 450 seconds in all three groups during CPB. Cell-
saving equipment (COBE BRAT II) was used in all three groups,
but with different treatment strategies. In groups I and II cell
saving was used before and after completion of CPB. In group III
the cell saver device was used throughout the surgical procedure
(including CPB). Cardiotomy suction was used in groups I and II
for the duration of CPB. Adequate anticoagulation was verified
every 15 minutes with the Heparin Management System
(Medtronic Perfusion Systems).
Transfusion protocol was directed by strict adherence to clin-
ical pathways. Patients were transfused with packed red blood cells
for a hematocrit less than 20% on CPB and less than 25% after
CPB. Platelets and appropriate transfusion factors were adminis-
tered in the postoperative period on the basis of laboratory and
coagulation data and for chest tube output exceeding 200 mL/h.
Processed blood from the cell saver was administered after CPB
and protamine administration in all cases.
Anesthesia and Extracorporeal Circulation
Anesthesia techniques were consistent across the three study
groups. Anesthesia induction and maintenance were performed
with fentanyl (initial intravenous bolus of 250 g followed by an
intravenous infusion of 1.8–2.4 g/[kg  h]), midazolam (5–10 mg
at induction), pancuronium, and etomidate. Isoflurane
(0.5%-1.5%) was used during the operation. Propofol (10 mL/h)
was used after CPB and in the ICU for sedation. Prophylactic
antifibrinolytic treatment with -aminocaproic acid (Amicar) was
routinely used; a 10-g intravenous load was followed by an intra-
venous infusion of 5 to 10 g/h throughout the operation. No
aprotinin was administered.
Bypass circuits were primed with Plasmalyte (Baxter Health-
care Corporation, Deerfield, Ill). The intravenous heparin load and
pump prime doses were based on an ACT target of 450 seconds
and calculated with the heparin dose-response assay (Hepcon
Instrument; Medtronic Perfusion Systems). During CPB additional
heparin was administered if the ACT fell below 450 seconds. The
pump flow rate was established at more than 2.4 L/(min  m2).
Blood cardioplegia and formulation techniques were uniform
among the three treatment groups. Minimal, systemic normother-
mia was used; lowest bladder temperatures were usually between
34°C and 36°C. Patients’ mean arterial pressures were maintained
at a minimum of 60 mm Hg with either phenlyephrine or isoflu-
rane, as needed. Processed cell saver contents were administered
intravenously after cessation of CPB.
Rewarming to 37°C was undertaken before weaning from CPB.
The protamine dose was calculated on the basis of the heparin
concentration at the conclusion of CPB with the Hepcon system. A
1:1 ratio of heparin to protamine was used.
Neuropsychologic Assessments
Neuropsychologic assessments were performed on subjects before
the operation in the clinic or on the hospital wards. Postoperative
testing was done at hospital discharge. A small battery of tests for
memory (Rey Auditory Verbal Learning Test [RAVLT]), symbol
discrimination and processing (Symbol Digit Modality Test
[SDMT]), visual acuity (Clock Drawing), and ability to categorize
(Category Fluency–Animals) were performed. Scores at discharge
visits were subtracted from baseline scores on a per patient basis.
Blood Sampling
Blood samples for laboratory marker analyses were drawn from
radial artery line. Blood samples were drawn at baseline (after
anesthesia induction, before bypass), at 5 minutes on bypass, after
bypass (just after protamine), 4 hours after bypass, and on the first
postoperative day. Blood samples were obtained by venipuncture
on postoperative day 2.
Laboratory Assays
Laboratory markers for inflammation (PMNE), interleukin (IL) 6
and IL-8, coagulation (PF-1.2), platelet activation (-thrombo-
globulin [–TG], platelet factor 4 [PF-4], soluble P-selectin),
terminal complement activation (C5b-9), neuronal injury (NSE,
S100) and fibrinolysis (tissue-type plasminogen activator [tPA],
plasminogen activator inhibitor [PAI-1]) were assayed in all study
patients. For PF-1.2 measurements, blood was collected into (FPR-
chloromethylketone) sodium citrate (PPAK) tubes and plasma was
assayed by a monoclonal antibody–sandwich enzyme-linked im-
munoassay (ELISA) technique (Enzygnost F12 Micro; Dade
Behring Marburg GmbH, Marburg, Germany). For PMNE, ci-
trated plasma was assayed with a heterogeneous enzyme immu-
noassay composed of a complex between PMNE and -proteinase
inhibitor followed by binding of alkaline phosphatase antibodies to
the -P1 end of the complex, which was measured photometrically
(Merck kit from EM Science, Gibbstown, NJ). IL-6 was assayed
from ethylenediaminetetraacetic acid (EDTA)–prepared plasma by
ELISA (catalog Nos. MAb 206 and BAF-206, R&D Systems, Inc,
Minneapolis, Minn; catalog No. A2004, Vector Laboratories, Inc,
Burlingame, Calif). IL-8 was also assayed from EDTA-prepared
plasma by ELISA (catalog Nos. M801 and M802-B, Endogen, Inc,
Woburn, Mass; catalog No. A2004, Vector). For PF-4 and -TG
measurements, blood was collected into previously cooled tubes
containing a solution of citric acid, theophylline, adenosine, and
dipyridamole, and plasma was assayed by ELISA (Diagnostica
Stago). P-selectin was measured in citrated plasma by ELISA
(catalog No. BBE 6; R&D Systems). tPA activity was assayed
using monoclonal antibody to tPA (SP-322) followed by chromo-
genic detection of the plasmin-sensitive substrate (catalog No.
1103, Biopool, Inc, Umea, Sweden). tPA activity was assayed
using plasma prepared from blood collected into Stabilyte tubes
(Biopool), which are necessary to prevent PAI-1 from quenching
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tPA activity in the sample. PAI-1 activity was measured in citrated
plasma with an immunofunctional method. Plasma was added to
microtiter plates coated with active tPA. Active PAI-1 in the
sample bound to the active tPA to form tPA/PAI-1 complex, which
was measured with an anti–PAI-1-horseradish peroxidase conju-
gate (Chromolize PAI-1; Biopool).
For C5b-9 measurements, EDTA-treated plasma was assayed by
ELISA (catalog No. A009, QUIDEL Corporation, San Diego,
Calif). NSE and S100 were measured in serum by ELISA
(SMART Kits; Skye PharmaTech Inc, Mississauga, Ontario, Can-
ada). All laboratory data are reported as back-transformed log10
mean and log10 mean  SEM.
Statistical Analysis
Comparison of laboratory data across the three treatment groups,
primarily after bypass, the point at which most laboratory markers
peaked, was performed by analysis of variance (ANOVA), with
the Scheffe´ test used for multiple comparisons among the three
treatment groups. Increases in laboratory markers with time rela-
tive to baseline levels were evaluated by ANOVA for repeated
measures. SPSS statistical software (version 8.0; SPSS Inc, Chi-
cago, Ill) was used. Laboratory data were scrutinized for normality
by means of normal probability Q-Q plots and log-transformed
before ANOVA procedures to stabilize variance between the
groups.
Demographic and clinical variables were analyzed by ANOVA
for continuous variables or the 2 test for categorical variables.
Data were tabulated as mean  SD for continuous data or number
of cases and percent of total in each group for categorical data.
Bleeding and transfusion data were compared by nonparametric
methods (Kruskal-Wallis test) followed by ANOVA with Scheffe´
test.
Laboratory data were tested for correlations by the Pearson
correlation coefficient. Neuropsychologic data were analyzed by
applying ANOVA to differences between baseline and follow-up
scores.
Results
After institutional review board approval to proceed with
the research was obtained, 42 subjects gave written consent
to participate in the research study from April 1, 2000, to
March 30, 2001. Six subjects were excluded before or
during the operation because autologous blood from the cell
saver was transfused during the operation, the time frame of
surgery changed, the subject withdrew before the operation,
the heparinization protocol was not followed, or a ventric-
ular aneurysm was discovered during the operation. Demo-
graphic data on 36 evaluable subjects, 12 subjects per
group, showed no differences between groups (Table 1).
Prognostic variables were distributed evenly across treat-
ment groups. Operative data were scrutinized for adherence
to the heparinization scheme, and no differences were evi-
dent between groups except for cell saver volume at the end
of CPB, which was significantly greater (by approximately
TABLE 1. Demographic and preoperative data
Variable Group I (n  12) Group II (n  12) Group III (n  12)
Age (y) 66 10 65 11 65 8
Gender (male/female ratio) 8:4 (67%:33%) 9:3 (75%:25%) 11:1 (92%:8%)
Body surface area (m2) 2.01 0.2 2.02 0.18 2.08 0.17
Left ventricular ejection fraction (%) 50 9 54 15 48 9
Hypertension 11/12 (92%) 12/12 (100%) 11/12 (92%)
Diabetes mellitus (dietarily controlled plus
insulin-dependent plus non-insulin-
dependent diabetes)
3/12 (25%) 2/12 (17%) 3/12 (25%)
Previous cerebrovascular accident 3/12 (25%) 1/12 (8%) 1/12 (8%)
Previous myocardial infarction 4/12 (33%) 4/12 (33%) 4/12 (33%)
Chronic obstructive pulmonary disease 2/12 (17%) 3/12 (25%) 3/12 (25%)
Previous use of anticoagulants 9/12 (75%) 8/12 (58%) 7/12 (58%)
Data are expressed as mean  SD for continuous variables and as number affected/number in group and percentage in group for categorical variables.
P values are based on ANOVA with Scheffe´ post hoc tests or 2 for categorical variables; all comparisons P  .20.
TABLE 2. Operative data
Variable
Group I
(n  12)
Group II
(n  12)
Group III
(n  12)
P value
I vs II I vs III II vs III
CPB time (min) 80 27 87 29 82 21 .20 .20 .20
Crossclamp time (min) 59 23 70 27 68 21 .20 .20 .20
No. of grafts 3.5 1.0 3.5 1.2 3.8 0.9 .20 .20 .20
ACT average mid CPB (s) 459 50 475 55 477 110 .20 .20 .20
Cell saver volume (mL) 786 201 815 161 999 251 .20 .056 .11
Operative variables are expressed as mean  SD. P values are based on ANOVA with Scheffe´ test.
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200 mL) in group III than in groups I and II (Table 2). All
other perfusion variables (total crystalloid pump prime,
cardioplegia and heparin doses, protamine reversal dose,
and heparin levels during CPB) were not different between
groups (data not shown).
Clinical End Points
Chest tube output measured at 24 hours was not different
between groups (data not shown). Homologous transfu-
sions, represented as total homologous donor units, were
reduced by 5.9 units in group II versus group I (P  .007)
and 6.5 units in group III versus group I (P .003, medians
7.0 vs 2.0 vs 1.5 units for groups I, II, and III, respectively;
Table 3). Most transfusions were administered in the first 24
hours after CABG. Of the patients who received transfu-
sions, 70% in group I (n 7/10), 71% in group II (n 5/7),
and 100% in group III (n  8/8) were transfused within the
first 24 hours. Baseline hematologic characteristics were
similar between treatment groups. Hematocrit and hemo-
globin were lower on average in group I immediately after
CPB and on postoperative day 2 than in groups II and III but
were similar at hospital discharge, despite differences in the
transfusion rates (Table 4). Platelet counts were also lower
on average in group I after CPB but similar by discharge
across groups, suggesting adherence to the transfusion pro-
tocol.
Coagulation was better preserved after CPB in group III
than in groups I and II, as reflected by platelet count,
fibrinogen, and thromboelastography (TEG), a measure of
clot strength. Fibrinogen was similar at baseline but higher
by approximately 70 mg/dL in group III than groups I (P 
.023) and II (P  .038) immediately after CPB.
TEG values for three of the four measured parameters
(r,,, and maximum amplitude [MA]) were more nearly in
the reference range in group III than in groups I and II. TEG
 was lower by approximately 1.2 mm in group III than in
groups I (P  .09) and II (P  .043). TEG MA, the main
gauge of clot strength, was higher by approximately 6 to 8
mm (59 mm is normal) in group III than in groups I (P 
.016) and II (P  .001). Finally, the angle (TEG ) was
higher (64° is normal) in group III than in groups I and II
(P  .01). Results of clinical chemistry panels performed
throughout the hospital stay were similar between groups
(data not shown).
Postoperative duration of ventilatory support was lower
by 3.0 hours in group III than in groups I and II, but this
difference did not reach statistical significance (P  .20;
Table 5). Complications and hospital stay were also similar
between groups. One subject in group I, who was at ex-
tremely high risk for central nervous system complications,
died 3 weeks after CABG of a dense cerebrovascular acci-
dent after a coronary angiogram to evaluate atypical chest
pain. One subject in group I returned to the operating room
because of postoperative bleeding.
Laboratory Results
Baseline levels of all laboratory markers studied were de-
termined and showed no differences between groups except
for tPA, which was lower by 0.4 U/mL in group I than in
group II (P  .02). All markers increased significantly and
peaked immediately after CPB, except for IL-6 and P-
selectin, which peaked 4 hours after CPB.
Thrombin generation (PF-1.2) was reduced by 3.5
nmol/L in group III relative to group I (P .001) and by 1.5
nmol/L relative to group II (P  .042) at the post-CPB time
point (Table 6, Figure 1). Consistent with other reports, tPA
TABLE 3. Transfusion data
Packed red
blood cells Platelets
Total donor
units
Group I (n  12)
No. of units transfused (mean  SD) 2.8 2.3 3.0 4.0 8.2 6.6
No. of units transfused (median) 2 0 7
Percentage of homologous units transfused 83 33 100
Group II (n  12)
No. of units transfused (mean  SD) 1.8 1.8 0.5 1.7 2.3 2.9
No. of units transfused (median) 2 0 2
Percentage of homologous units transfused 58 8 58
Group III (n  12)
No. of units transfused (mean  SD) 1.7 1.5 0.0 0.0 1.7 1.5
No. of units transfused (median) 1.5 0 1.5
Percentage of homologous units transfused 67 0 67
P value
I vs II .20 .069 .007
I vs III .20 .024 .003
II vs III .20 .20 .20
Kruskal-Wallis test and ANOVA used.
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was reduced by 8.4 U/mL with use of HBCs in group II
versus group I (P  .016) 5 minutes into CPB, at which
time the fibrinolytic response is known to rapidly increase.
tPA was reduced even further, by 9.0 U/mL, with the
elimination of cardiotomy suction in group III versus group
I (P  .003) 5 minutes into CPB. No further measurements
of tPA were performed, because its time course is known to
peak during CPB and return to baseline after protamine
reversal. PAI-1, on the other hand, is known to increase
after protamine reversal, through the period in the ICU and
postoperative day 1. PAI-1 was measured in a subset of
patients (n  7, n  7, n  8, groups I-III, respectively) and
rose in all treatment groups by postoperative day 1. The large
variability in PAI-1 made it difficult to draw any conclusions,
however, especially with the reduced sample size.
Inflammation (PMNE, IL-6, IL-8, and C5b-9) was gen-
erally reduced with the addition of HBCs and further re-
duced with the elimination of cardiotomy suction (Table 7).
Specifically, PMNE was reduced by 180 g/mL in group II
versus group I (P  .027) and by 235 g/mL in group III
versus group I (P  .001) at the post-CPB time point
(Figure 2). Complement C5b-9 was reduced by 284 ng/mL in
group III versus group I (P  .026) and by 284 ng/mL in
group III versus group II (P  .021). C5b-9 levels had
returned to baseline by 4 hours after CPB. IL-6 levels 4
hours after CPB were lower by 82 pg/mL in group II than in
TABLE 4. Clinical laboratory data
Group I
(n  12)
Group II
(n  12)
Group III
(n  12)
P value
I vs II I vs III II vs III
Hematocrit (%)
Baseline 40.7 3.8 42.8 3.2 41.0 4.4 .20 .20 .20
After CPB (in operating room) 25.3 2.3 27.1 2.9 26.6 3.8 .20 .20 .20
Postoperative day 2 24.9 3.3 28.3 3.0 27.2 2.9 .062 .20 .20
Postoperative day 4 or discharge 28.2 3.4 29.2 2.5 28.4 2.7 .20 .20 .20
Hemoglobin (g/dL)
Baseline 13.6 1.7 14.6 0.9 13.9 1.3 .20 .20 .20
Postoperative (ICU) 11.1 1.4 11.1 1.4 11.3 1.4 .20 .20 .20
Postoperative day 2 8.8 1.2 9.8 0.9 9.6 1.1 .109 .244 .20
Postoperative day 4 or discharge 9.5 1.1 9.9 0.9 9.5 1.0 .20 .20 .20
Platelet count (103 cells/L)
Baseline 225 66 204 43 227 53 .20 .20 .20
After CPB (in operating room) 143 53 148 26 177 42 .20 .15 .20
Postoperative day 2 130 30 119 28 143 49 .20 .20 .20
Postoperative day 4 or discharge 210 57 173 48 203 62 .20 .20 .20
Fibrinogen (mg/dL)
Baseline 443 56 384 63 431 115 .20 .20 .20
After CPB (in operating room) 204 61 209 45 274 52 .20 .023 .038
International normalized ratio
Baseline 1.0 0.1 1.1 0.2 1.0 0.1 .20 .20 .20
After CPB 1.3 0.2 1.3 0.1 1.2 0.1 .20 .20 .20
Prothrombin time (s)
Baseline 11.0 1.0 11.6 1.6 10.7 0.6 .20 .20 .20
After CPB 14.0 1.6 14.1 1.6 12.8 0.8 .20 .20 .20
TEG
Post-CPB r (mm) 12.3 4.2 14.3 5.5 12.1 2.6 .20 .20 .20
Post-CPB  (mm) 4.0 1.3 4.2 0.8 2.9 0.9 .20 .09 .043
Post-CPB  (degrees) 66.9 6.2 63.1 5.2 72.8 5.5 .20 .152 .010
Post-CPB MA (mm) 57.8 6.3 55.6 3.5 64.3 2.2 .20 .016 .001
Data are mean  SD. P values are based on ANOVA of data with Scheffe´ post hoc tests.
TABLE 5. Outcomes
Variable
Group I
(n  12)
Group II
(n  12)
Group III
(n  12) P value
Intubation time in ICU (h, mean  SD) 7.0 6.7 7.0 7.9 4.0 2.4 .20
Hospital stay (d, mean  SD) 6.8 4.3 5.2 1.0 6.5 2.8 .20
Perioperative mortality (no.) 1 (8%) 0 (0%) 0 (0%) .20
The 2 test was used for categorical data; ANOVA was used for continuous variables.
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group I (P  .20) and by 79 pg/mL in group III than group
I (P  .20). Post-CPB IL-8 levels were lower by 7.7 pg/mL
in group II than in group I (P  .19) and by 7.9 pg/mL in
group III than in group I (P .18). Despite these trends, the
post-CPB IL-6 and IL-8 results did not reach statistical
significance, perhaps because of the small sample size.
Platelet activation, as measured by -TG and PF-4, was
reduced immediately, 5 minutes into CPB, in groups III
versus group I (P  .001) and remained lower at the
post-CPB time point (Table 8). In particular, post-CPB
-TG was lower by 1779 IU/mL in group II than in group
I (P  .001) and by 2046 IU/mL in group III than in group
I (P  .001; Figure 3). Elimination of cardiotomy suction
(group III vs group II) reduced post-CPB -TG by a further
266 IU/mL (P  .20). Furthermore, platelet function, as
measured by TEG, was also better preserved in group III
(Table 4). Addition of heparin-bonded circuitry did not
impart an effect on either of the neuronal injury markers,
NSE nor S100 (Figure 4). Elimination of cardiotomy in
group III, however, reduced NSE to baseline levels com-
pared with both groups I and II (P  .001). Similarly,
elimination of cardiotomy reduced S100 to baseline levels
compared with group I (P  .005) and group II (P  .05).
Pairs of laboratory assay measurements were plotted
against each other, and the plots showed approximate linear
relationships. Post-CPB platelet activation markers, -TG
in particular, were strongly correlated with inflammation
(PMNE; Figure 5). These markers also correlated signifi-
cantly with thrombin (r  0.63 and r  0.57, respectively,
P  .01).
Neurocognitive function (SDMT and RAVLT) at hospi-
tal discharge was better preserved (no deficits from base-
line) in group III (Figures 6 and 7). Patients who were
assessed at baseline (10/12 in group I, 11/12 in group II, and
9/12 in group III) were 80% to 100% compliant at dis-
charge, depending on the test.
Discussion
This study was designed to assess and disassociate the
independent effects of cardiotomy suction and HBCs on
systemic markers known to be elevated during and after
CPB. These included thrombin generation (PF-1.2) platelet
activation (PF-4, -TG, and P-selectin) and fibrinolysis
(tPA and PAI-1). In addition, the specific effects of cardiot-
Figure 1. Comparison of thrombin generation (PF-1.2) for different
treatment strategies. Diamonds, Group I; squares, group II; trian-
gles, group III. Asterisk indicates P < .001 for group I versus
group III; plus sign indicates P .042 for group II versus group III,
by ANOVA and Scheffe´ test.
Figure 2. Comparison of PMNE for different treatment strategies.
Diamonds, Group I; squares, group II; triangles, group III. Asterisk
indicates P < .001 for group I versus group III; plus sign indicates
P  .027 for group I versus group II, by ANOVA and Scheffe´ test.
Figure 3. Comparison of platelet activation (-TG) for different
treatment strategies. Diamonds, Group I; squares, group II; trian-
gles, group III. Asterisk indicates P < .001 for group I versus
group III; plus sign indicates P < .01 for group I versus group II,
by ANOVA and Scheffe´ test.
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omy suction and HBCs on markers of inflammation
(PMNE, C5b-9, IL-6, and IL-8) and neuronal injury (NSE
and S100) were assessed. Elevations in these markers had
previously been attributed to CPB procedures themselves
and to ischemia and reperfusion.
We hypothesized that expression of these markers can
also be significantly influenced by technique (use or elimi-
nation of cardiotomy suction), because cardiotomy suction
has been demonstrated to reintroduce particulate matter (fat
emboli) as well as procoagulant and proinflammatory fac-
tors and debris from the surgical field, into the systemic
circulation.19-23 These effects may blunt differences in out-
comes related to CPB equipment.
The study has several limitations. Its power was chosen
primarily to address effects of different therapies on mark-
ers of injury and was not sufficient to demonstrate major
clinical differences. It was also designed to disassociate the
effects of cardiotomy suction from those of HBCs. The aim
of the study was to define the effects of presence or absence
of cardiotomy suction when HBCs were used. Similarly, the
aim was to define specific effects of non-HBCs versus
HBCs when cardiotomy suction was used. By design, how-
Figure 4. A, Comparison of NSE for different treatment strategies. Diamonds, Group I; squares, group II; triangles,
group III. Asterisk indicates P < .001 for group I versus group III; plus sign indicates P < .001 for group II versus
group III, by ANOVA and Scheffe´ test. B, Comparison of S100 for different treatment strategies Diamonds, Group I;
squares, group II; triangles, group III. Asterisk indicates P  .005 for group I versus group III; plus sign indicates
P  .035 for group II versus group III, by ANOVA and Scheffe´ test.
TABLE 6. Coagulation and fibrinolysis
Group I (n  12) Group II (n  12) Group III (n  12)
P valueBack-transformed
log10 mean
Log10 mean
 SEM
Back-transformed
log10 mean
Log10 mean
 SEM
Back-transformed
log10 mean
Log10
mean  SEM I vs II I vs III II vs III
PF-1.2 (nmol/L)
Baseline 1.2 0.07 0.07 1.3 0.10 0.05 1.2 0.08 0.055 .20 .20 .20
5 min on CPB 1.5 0.18 0.08 1.1 0.047 0.051 1.1 0.025 0.025 .20 .20 .20
After CPB 5.0 0.70 0.85 3.0 0.47 0.093 1.5 0.19 0.19 .12 .001 .042
4 h after CPB 3.3 0.51 0.50 2.2 0.35 0.033 2.3 0.36 0.36 .053 .058 .20
tPA activity (U/mL)
Baseline 0.2 0.78 0.16 0.6 0.24 0.10 0.4 0.45 0.17 .02 .20 .20
5 min on CPB 10.5 1.02 0.22 2.1 0.33 0.14 1.5 0.17 0.08 .016 .003 .20
After CPB 1.7 0.24 0.16 1.7 0.22 0.16 1.6 0.19 0.17 .20 .20 .20
PAI-1 activity (U/mL)
Baseline 20.8 1.32 0.09 6.6 0.82 0.12 5.8 0.77 0.23 .14 .08 .20
5 min on CPB 1.2 0.08 0.43 1.2 0.08 0.41 2.5 0.39 0.39 .20 .20 .20
After CPB 11.8 1.07 0.17 8.5 0.93 0.22 2.6 0.42 0.38 .20 .20 .20
4 h after CPB 21.9 1.35 0.46 46.8 1.68 0.13 36.3 1.56 0.23 .20 .20 .20
Postoperative day 1 16.2 1.21 0.64 63.2 1.80 0.09 25.1 1.40 0.11 .20 .20 .20
P values are based on ANOVA of log10 data with Scheffe´ post hoc tests.
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ever, we did not specifically evaluate the effect of eliminat-
ing cardiotomy suction in patients treated with non-HBCs;
we did not attempt to make the assumption that the effect of
eliminating cardiotomy suction would be the same regard-
less of whether HBCs were used. Lower anticoagulation
(either through heparin or heparin-protamine complexes)
may further lead to a decreased expression of inflammation,
such as complement, neutrophil activation, interleukins, and
other markers, which were decreased but not blunted in our
patients treated with HBCs and kept at ACTs longer than
450 seconds. Finally, this study focused on patients under-
going isolated CABG with CPB. The relevance of these
findings to patients undergoing cardiac procedures that re-
quire much more extensive cardiotomy suction was not
evaluated. Despite these limitations, the study was able to
accomplish its stated objectives.
The findings of this study support our hypothesis that the
use of cardiotomy suction (particularly with non-HBC cir-
cuits) significantly increases post-CPB expression of mark-
ers for thrombin generation, inflammation, platelet activa-
tion, and neuronal injury. The use of HBCs, even when
cardiotomy suction was used, significantly blunted platelet
activation and fibrinolysis. The use of HBCs with cardiot-
omy suction, however, resulted in intermediate expression
of markers for thrombin and inflammation but had no effect
on elevation of markers of neuronal injury (NSE and
S100). Finally, with elimination of cardiotomy suction
(group III), thrombin generation, PMNE, and neuronal in-
jury markers were nearly completely blunted relative to
groups I and II. Complement C5b-9 was significantly re-
duced in group III relative to groups I and II but not to
baseline levels. The use of HBCs with or without cardiot-
Figure 5. Correlation of post-CPB log10 PMNE and log10 -TG.
Diamonds, Group I; squares, group II; triangles, group III; line,
total population. Pearson r  0.75, P < .01.
Figure 6. Delayed memory, RAVLT VIII, by treatment group (box
plots of difference scores). Score is based on asking patient to
list as many of 15 words as are remembered after 20-minute
break. P  .126 for group I versus group III, P > .20 for group II
vs group III, by ANOVA and Scheffe´ test applied to difference
scores.
Figure 7. Symbol discrimination, written SDMT, by treatment
group (box plots of difference scores). P  .054 for group I versus
group III, P  .003 for group II versus group III, by ANOVA and
Scheffe´ test applied to difference scores.
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omy suction diminished IL-6 and IL-8 levels in groups II
and III relative to group I, but this difference did not reach
statistical significance. The use of HBCs with or without
cardiotomy suction had no detectable effect on PAI-1 or
P-selectin, although there was a trend toward reduced P-
selectin at 4 hours after CPB in group III relative to groups
I and II.
A significant correlation between markers of inflamma-
tion (PMNE) and platelet activation (-TG, r  0.75; Fig-
ure 5) as well as thrombin generation was also demon-
strated. This suggests a possible common pathway or cross-
activation.
Finally, we demonstrated that neurocognitive function,
as measured by SDMT and RAVLT testing, was better
preserved at discharge in group III.
The data from this study suggest that differences in the
reported efficacy of HBCs for patients undergoing CABG
may have been affected not only by differences in antico-
agulation protocols (full vs lower) but by important differ-
ences in surgical technique (use of cardiotomy suction),
which may significantly abrogate the benefits conferred by
HBCs. More important, the study challenges several com-
monly accepted precepts of cardiac surgery. One such no-
tion is the belief that the use of cardiotomy suction and open
systems, which are used ubiquitously (90% of patients), is
safe. This study supports previous studies19-23 that demon-
strated a deleterious effect of cardiotomy suction and sug-
gests that cardiotomy suction use should be avoided when-
ever possible. This is relatively simple in CABG procedures
because of minimal intraoperative mediastinal drainage (ap-
proximately 200 mL in this study). Use of cell saver tech-
niques for these patients would not result in clinically sig-
nificant loss of important components of whole blood and
plasma. Further studies are necessary to develop effective
strategies to blunt these deleterious effects when open sys-
tems and cardiotomy suction are required (more invasive
cardiac procedures).
Another commonly held precept is that CPB results in an
obligatory, unalterable systemic insult. These data suggest
that avoidance of cardiotomy suction and the use of HBCs
with a closed circuit (collapsible reservoir), elimination of
blood-air interface, and defoaming agents can blunt many of
these deleterious effects. Further pharmacologic approaches
may be more effective once much of the perturbation has
been significantly blunted to the levels achieved by this
technique and equipment. Moreover, much of the current
impetus for performing off-pump CABG is driven by the
desire to avoid the perturbations in coagulation and inflam-
TABLE 7. Inflammation
Group I (n  12) Group II (n  12) Group III (n  12)
P value
Back-
transformed
log10 mean
Log10 mean
 SEM
Back-
transformed
log10 mean
Log10 mean
 SEM
Back-
transformed
log10 mean
Log10 mean
 SEM I vs II I vs III II vs III
PMNE 1.2 (g/mL)
Baseline 29.5 1.47 0.103 36.3 1.56 0.065 32.4 1.51 0.048 .20 .20 .20
5 min on CPB 55.0 1.75 0.081 33.1 1.52 0.075 26.3 1.41 0.051 .084 .009 .20
After CPB 307.1 2.49 0.104 127.8 2.11 0.093 74.6 1.87 0.086 .027 .001 .20
4 h after CPB 114.8 2.06 0.081 77.6 1.89 0.039 46.8 1.67 0.066 .2 .001 .07
Postoperative day
1
81.3 1.91 0.124 77.6 1.89 0.095 95.5 1.98 0.12 .20 .20 .20
IL-6 (pg/mL)
Baseline 3.0 0.47 0.11 3.1 0.49 0.09 4.3 0.63 0.11 .20 .20 .20
5 min on CPB 4.2 0.62 0.07 3.5 0.54 0.09 5.4 0.73 0.09 .20 .20 .20
After CPB 67.6 1.83 0.12 36.3 1.56 0.09 33.1 1.52 0.09 .16 .101 .20
4 h after CPB 213.8 2.33 0.07 131.8 2.12 0.11 134.9 2.13 0.08 .20 .20 .20
IL-8 (pg/mL)
Baseline 3.2 0.51 0.06 3.6 0.56 0.05 3.9 0.59 0.10 .20 .20 .20
5 min on CPB 4.1 0.61 0.09 4.5 0.65 0.07 4.2 0.62 0.08 .20 .20 .20
After CPB 16.2 1.21 0.14 8.5 0.93 0.07 8.3 0.92 0.10 .19 .18 .20
4 h after CPB 16.2 1.21 0.10 11.0 1.04 0.07 12.3 1.09 0.08 .20 .20 .20
Terminal complement
C5b-9 (ng/mL)
Baseline 0.1 0.99 0.52 0.6 0.25 0.54 0.6 0.25 0.54 .20 .20 .20
5 min on CPB 138.0 2.14 0.42 354.8 2.55 0.03 275.4 2.44 0.08 .20 .20 .20
After CPB 741.3 2.87 0.05 741.3 2.87 0.03 457.1 2.66 0.07 .20 .026 .021
4 h after CPB 0.4 0.45 0.82 0.21 0.67 0.58 0.74 0.13 0.57 .20 .20 .20
P values are based on ANOVA of log10 data with Scheffe´ post hoc tests.
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mation and the neuropsychologic injuries that are associated
with CPB. In the absence of large, prospective, randomized
trials, our data suggest that many of the deleterious effects
previously attributed to CPB can be avoided when cardiot-
omy suction is eliminated and HBCs are used. The signif-
icant elevation in markers of neuronal injury associated with
on-pump CABG, and avoided by off-pump CABG, were
blunted in this study, suggesting a better standard for future
comparisons with off-pump CABG.
It is probable that significant elevations in NSE and
S100 seen in patients treated with cardiotomy suction do
not represent direct cerebral injury but rather extracerebral
sources, such as pump trauma (fat or ruptured platelets and
red blood cells).25-36 This is supported by our data, which
demonstrated no significant differences between groups or
from baseline levels by the first postoperative day. Expression
of these markers, regardless of their specific source, although
not clearly representing direct causality, is associated with
deleterious outcomes and deficits in neurocognitive function.
In summary, elimination of cardiotomy suction was easy
to effect for patients undergoing CABG and resulted in a
minimal increase in cell saver blood. The combination of
HBCs with elimination of cardiotomy suction blunted many
of the deleterious effects of CPB on markers of coagulation,
inflammation, and neuronal injury and should be used
whenever possible to enhance clinical outcomes. Future
research is needed to further elucidate these mechanisms.
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Discussion
Dr Andrew S. Wechsler (Philadelphia, Pa). Aldea and col-
leagues appear to have demonstrated that the use of HBCs in the
CPB system diminishes activation of inflammatory markers, di-
minishes the coagulation and lytic response to bypass, diminishes
white blood cell and platelet activation, and may provide some
clinical benefit. Avoidance of cardiotomy suction further enhanced
the benefit accrued by the use of HBCs. I have a few observations
and questions.
First, your patient population was carefully selected, cross-
clamp times were short, and CPB times were short. One could
argue that the differences between groups that were observed
would be enhanced in the setting of more complex operations.
Alternatively, if the stimulus were great enough, the differences
observed might be obscured by greater activation of inflammatory
and coagulation markers. What do you think?
Dr Aldea. I think that the former is possible. In fact, there are
two patient populations that we look at. One is a CABG popula-
tion. Typically the amount of cardiotomy suction is rather limited
in volume, as I have shown here, so there is a potential that in more
complex intracardiac procedures the much more extensive blood-
air interaction and greater cardiotomy volume would lead to more
inflammation. These effects would be accentuated. We are in the
process of designing a study to look at these differences, and I
think that this comment is correct. We expect that there will be
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much more accentuated effects in settings when cardiotomy suc-
tion and blood-air interfaces are increased.
Dr Wechsler. Second, your studies were performed at “mod-
erate systemic hypothermia.” This is a somewhat vague term, and
it would be important to know the perfusate temperature during
CPB. Do you agree that hypothermia appears to exacerbate the
inflammatory and thrombotic cascade?
Dr Aldea. What we did in this particular study and in our
previous studies is what we term “near-normothermia,” that is, that
there is no active cooling. Typically the patient’s temperature drifts
to approximately 35°. In fact, if it drifts below that we actively
start rewarming. There is no question that there is an effect of
hypothermia on coagulation, with accentuated coagulopathy. I am
not sure what the effect would be on inflammatory changes. In this
particular study we controlled for the temperature, so I think that the
effects are predominantly related to the elimination of cardiotomy.
Dr Wechsler. I am a little concerned about one aspect of your
experimental design. Why did you not keep the cardiotomy reser-
voir constant across all groups? Is it possible that using a collaps-
ible heparin-bonded reservoir in the HBC group without cardiot-
omy suction might have contributed to the diminution of
inflammation and coagulation disorders relative to the hard-shell
heparin-coated reservoir used for the patients who had cardiotomy
suction? By using two different reservoirs, have you potentially
obviated the difference between cardiotomy suction and incrimi-
nated the type of reservoir? The blood-air interface may be as
important as the suction per se.
Dr Aldea. That is a good question. My impression in having
measured some of the contents of cardiotomy suction is that there
is an independent effect of blood-air interaction that could poten-
tially increase coagulation abnormalities. However, the effect of
particulate matter was shown by Stump’s work demonstrating an
increasing number of cerebral emboli, which are probably related
to fat embolization and other particulate matter from the wound
not filtered by arterial filters. This effect, as well as other proco-
agulant and proinflammatory factors, are independent of the phys-
ical shape of the reservoir itself. I think that the effects are real, and
I do recognize that there was an issue with that. We have tried to
correct for it as much as possible.
Dr Wechsler. You apparently used two different oxygenators,
one in the non-HBC group and one in the HBC groups. Could this
have contributed to some of the observed differences?
Dr Aldea. Again, the main differences we believe are due to
the cardiotomy suction, and the reason we can support this is the
differences we measured with the cardiotomy suction per se. Those
were the oxygenators available to us. There was only a small
variation between them related to the configuration of the
non-HBC system that was available to us for the purpose of the
study.
Dr Wechsler. Your study was designed thoughtfully, with
careful power calculations to determine differences noted between
inflammatory and thrombotic markers. However, in your analysis
you attempted to correlate isolated clinical variables with these
measurements, specifically lung compliance and transfusion units.
The correlation coefficients are not particularly convincing, and I
wonder whether you have gone further with your data than is
actually justified. For such a comparison to be valid, one would
have to use a protocol that included specific transfusion triggers,
which were not specified in your article.
Dr Aldea. We did have specific transfusion triggers and a
protocol in place, and all transfusion was triggered by clinical
pathways and TEG, as well as actual amount of bleeding, so that
was accounted for. I think that the criticism that the study was not
designed to look at clinical end points but rather at laboratory
markers is correct. The study was designed on the basis of previous
data that demonstrated that with the use of HBCs we can decrease
the expression of these laboratory markers by approximately 50%.
We were, however, surprised that despite this we could make some
associations with clinical end points and just wanted to emphasize
the point that these markers are not of just biochemical interest but
are of some clinical relevance.
Dr Wechsler. Some investigators have demonstrated that pro-
tein coating of bypass circuits is equally effective in minimizing
adverse markers associated with CPB. Do you believe that heparin
plays a unique role in the answer, could the answer be found in
other natural or synthetic surface coatings?
Dr Aldea. This is a difficult question to answer. I think you
have to test each individual circuit. I think that it is problematic to
take a concept that the coatings themselves, which within minutes
are coated by secondary protein layers, have similar properties. We
know that different coatings may exert different properties. We
know that some coatings protect from platelet dysfunction but do
not necessarily diminish the inflammatory response to CPB, so I
think that this is a problematic area. When new products are
introduced, I believe that they must be rigorously tested to make
sure that in fact they have the same efficacy as the well-tested
circuits that exist now and have withstood the scrutiny of a large
clinical experience.
Dr Wechsler. Could you comment as to whether any of the
data were accrued in a blinded fashion? I would assume that this
was the case for all the laboratory data but not the case for the
clinical data. Is this correct?
Dr Aldea. All the surgeons were blinded to treatment group
at the time of surgery, and the caregivers were blinded after-
ward.
Dr Wechsler. These questions were designed to stimulate
some discussion and not to detract from the quality of this excel-
lent study. I commend you and your colleagues for attempting to
sort out those factors most responsible for the adverse events
associated with CPB that may be influenced by heparin bonding or
procedural strategies.
Dr Gregory Misbach (San Bernadino, Calif). Can you give us
any hints on how best to minimize cardiotomy suction in a variety
of cases, including for instance valve operations? Are there any
particular strategies that you would recommend to help us receive
the benefits of what you are showing us today?
Dr Aldea. This study was designed primarily to look at the
CABG population, and again if you look at this moment at clinical
practice in the United States more than 95% of centers are using
routine cardiotomy suction when CPB is used during CABG. What
we have shown is that in fact the amount of fluid that you get when
you use cardiotomy suction during routine CABG, even a reop-
eration, is quite small, whereas the detrimental effects are signif-
icant. I think that one has to rethink and redesign cardiotomy
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suction if these effects can be demonstrated for patients undergo-
ing more invasive cardiac procedures, such as valve replacement.
There are two implications. First, we might have to change the
filtration system. Second, I think that the biggest variable is the
stagnant pericardial blood. It may be that because in valve proce-
dures you do not have the stagnation and the active biologic
surfaces of the pericardium to deal with, the results may be
different. The relevance of the application of this concept to
pediatric cases and intracardiac cases has to be carefully looked
at.
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